158 related articles for article (PubMed ID: 38429698)
21. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
[TBL] [Abstract][Full Text] [Related]
22. Breakthrough cancer pain and rational drug use.
Olarte JM
Support Care Cancer; 2017 Apr; 25(Suppl 1):11-17. PubMed ID: 28213817
[TBL] [Abstract][Full Text] [Related]
23. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.
Mercadante S; Valle A; Porzio G; Aielli F; Adile C; Ficorella C; Raineri M; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):667-71. PubMed ID: 23551065
[TBL] [Abstract][Full Text] [Related]
24. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough cancer pain: The importance of the right treatment at the right time.
O'Hagan P; Mercadante S
Eur J Pain; 2018 Aug; 22(7):1362-1374. PubMed ID: 29635732
[TBL] [Abstract][Full Text] [Related]
26. Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
Tuca Rodríguez A; Núñez Viejo M; Maradey P; Canal-Sotelo J; Guardia Mancilla P; Gutiérrez Rivero S; Raja Casillas I; Herrera Abián M; López Bermudo C
Support Care Cancer; 2021 Aug; 29(8):4799-4807. PubMed ID: 33533986
[TBL] [Abstract][Full Text] [Related]
27. Breakthrough pain in patients with multiple myeloma: a secondary analysis of IOPS MS study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1134-1139. PubMed ID: 36808361
[TBL] [Abstract][Full Text] [Related]
28. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
Romualdi P; Candeletti S
Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
[TBL] [Abstract][Full Text] [Related]
29. Understanding the Experience of Cancer Pain From the Perspective of Patients and Family Caregivers to Inform Design of an In-Home Smart Health System: Multimethod Approach.
LeBaron V; Bennett R; Alam R; Blackhall L; Gordon K; Hayes J; Homdee N; Jones R; Martinez Y; Ogunjirin E; Thomas T; Lach J
JMIR Form Res; 2020 Aug; 4(8):e20836. PubMed ID: 32712581
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.
Canal-Sotelo J; Trujillano-Cabello J; Larkin P; Arraràs-Torrelles N; González-Rubió R; Rocaspana-Garcia M; Barallat-Gimeno E
BMC Palliat Care; 2018 May; 17(1):81. PubMed ID: 29807537
[TBL] [Abstract][Full Text] [Related]
31. Deploying the Behavioral and Environmental Sensing and Intervention for Cancer Smart Health System to Support Patients and Family Caregivers in Managing Pain: Feasibility and Acceptability Study.
LeBaron V; Alam R; Bennett R; Blackhall L; Gordon K; Hayes J; Homdee N; Jones R; Lichti K; Martinez Y; Mohammadi S; Ogunjirin E; Patel N; Lach J
JMIR Cancer; 2022 Aug; 8(3):e36879. PubMed ID: 35943791
[TBL] [Abstract][Full Text] [Related]
32. Leveraging Smart Health Technology to Empower Patients and Family Caregivers in Managing Cancer Pain: Protocol for a Feasibility Study.
LeBaron V; Hayes J; Gordon K; Alam R; Homdee N; Martinez Y; Ogunjirin E; Thomas T; Jones R; Blackhall L; Lach J
JMIR Res Protoc; 2019 Dec; 8(12):e16178. PubMed ID: 31815679
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.
Ferrero VT; Oset MM; Masferrer JP; Pardo EH; Sorolla EJ; Largo SC;
Clin Transl Oncol; 2019 Dec; 21(12):1707-1711. PubMed ID: 30949931
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough cancer pain in 2020.
Løhre ET; Thronæs M; Klepstad P
Curr Opin Support Palliat Care; 2020 Jun; 14(2):94-99. PubMed ID: 32332210
[TBL] [Abstract][Full Text] [Related]
35. A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.
Baek SK; Kim DY; Kang SY; Sym SJ; Kim YS; Lee JY
Cancer Res Treat; 2016 Apr; 48(2):768-74. PubMed ID: 26511815
[TBL] [Abstract][Full Text] [Related]
36. Interference with daily functioning by breakthrough pain in patients with cancer.
Kang JH; Koh SJ; Oh SY; Kim RB; Shin SH; Lee YG; Kim BS; Ryoo HM; Yoon SY; Jang JS; Oh HS; Choi YJ; Lee MH; Lee KH
Support Care Cancer; 2020 Nov; 28(11):5177-5183. PubMed ID: 32056013
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
38. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain.
Mercadante S; Adile C; Masedu F; Valenti M; Aielli F
J Pain Symptom Manage; 2019 May; 57(5):966-970. PubMed ID: 30822530
[TBL] [Abstract][Full Text] [Related]
39. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).
Porta-Sales J; Pérez C; Escobar Y; Martínez V
Clin Transl Oncol; 2016 Sep; 18(9):945-54. PubMed ID: 26693731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
